上海富雨生物科技有限公司
初级会员 | 第1年

18956075901

当前位置:上海富雨生物科技有限公司>>细胞库 / 细胞培养>>普通细胞>> SNU-398人肝癌细胞(附S

SNU-398人肝癌细胞(附S

参  考  价面议
具体成交价以合同协议为准

产品型号

品       牌

厂商性质生产商

所  在  地

更新时间:2025-02-11 18:16:16浏览次数:58次

联系我时,请告知来自 化工仪器网
同类优质产品更多>
人肝癌细胞SNU-398种属人别称SNU398; NCI- SNU- 39 8组织来源肝脏疾病肝细胞癌传代比例/细胞消化1:2传代 ,消化1-3分钟,培养基配置RPMI1640 培养基: 10%胎牛血清

人肝癌细胞SNU-398

种属
别称SNU398; NCI- SNU- 39 8
组织来源肝脏
疾病肝细胞癌
传代比例/细胞消化1:2传代 ,消化1-3分钟 ,
培养基配置RPMI1640 培养基: 10%胎牛血清 1%双抗
简介SNU-398 于 1990 年由 J.-G. Park 及其同事取自一名韩国患者的间变性肝细胞癌 ,该患者已通过脂质体加 和-C 的组合进行了经导管动脉栓塞治疗。既可以附着细胞也可以悬浮细胞。悬浮的细胞是可行 ,不应丢 弃。通过温和离心 (125 xg) 回收悬浮细胞 ,以与贴壁细胞群一起进行继代培养。
形态上皮细胞样
生长特征悬浮贴壁生长
倍增时间每周 2 3
抗原表达Blood Type O; Rh +
STRAmelogenin: X,Y CSF1PO: 13 D13S317: 11 D16S539: 10, 14 D5S818: 12 D7S820: 10, 11 THO1: 7,9 TPOX:11 vWA: 17, 18
保藏机构ATCC; CRL- 2233

Background: Hospitals face mounting pressure to reduce unplanned utilization amid rising healthcare demands from an aging population. The Case management for At-Risk patients in the Emergency Department (CARED) program is among the first ED transitional care strategies to focus on both frail older adults and Emergency Department (ED) re-attenders to reduce acute hospital utilization. This study aims to evaluate the effectiveness of the CARED program in reducing hospital (re)admissions and ED re-attendances within 30- and 60-days post-discharge.

Methods: A retrospective, propensity-matched study was conducted from April 2022 to July 2023 in the ED of Ng Teng Fong General Hospital in Singapore. The CARED program identifies and enrols at-risk patients i.e., frail older adults and patients who re-attend the ED within 30 days of hospital discharge, for a geriatric assessment. This is followed by multidisciplinary team care, discharge planning and right siting of care from the ED to community-based services by ED case managers. The primary outcomes were hospital (re)admissions and ED re-attendances within 30- and 60-days post-discharge. Secondary outcomes were cost avoidance and bed occupancy days from reduced acute hospital usage.



untreated host, most aeTSAs are undetected by the immune system. We present evidence suggesting that vaccines inducing direct aeTSA presentation by DCs may represent an attractive strategy for cancer treatment.Checkpoint inhibitors (eg, programmed cell death protein 1 [PD-1], programmed cell death ligand 1 [PD-L1], cytotoxic T-lymphocyte associated protein 4 [CTLA-4] antibodies) are changing how we understand cancer and provide a means to develop modern

会员登录

×

请输入账号

请输入密码

=

请输验证码

收藏该商铺

X
该信息已收藏!
标签:
保存成功

(空格分隔,最多3个,单个标签最多10个字符)

常用:

提示

X
您的留言已提交成功!我们将在第一时间回复您~
拨打电话
在线留言